Hyun Hee Sul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hyun Hee Sul has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Matheus Souza
Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
4 shared publications - Pojsakorn Danpanichkul
Department of Internal Medicine Texas Tech University Health Sciences Center Lubbock Texas USA
4 shared publications - Saeed Ahmad
Beth Israel Deaconess Medical Center Harvard Medical School Boston Massachusetts USA
4 shared publications - Maxim Sergey Petrov
School of Medicine, University of Auckland, Auckland, New Zealand.
3 shared publications - Alessandro Mantovani
Metabolic Diseases Research Unit IRCCS Sacro Cuore‐Don Calabria Hospital Negrar di Valpolicella Italy
1 shared publication Charles N Bernstein
Department of Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, and University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre , Manitoba
1 shared publication
Latest Publications
- Open Access
- 19 October 2026
- Published by Wiley in Liver International
- Vol. 46 (11) , e70934
Excess Liver Fat in Type 2 Diabetes Stratified by Intrapancreatic Fat Deposition: A Meta‐Analysis of Dual‐Organ MRI Studies
Both liver fat content (LFC) and intrapancreatic fat deposition (IPFD) are frequently increased in Type 2 diabetes mellitus (T2DM). We meta‐analysed dual‐organ MRI studies comparing LFC between individuals with T2DM and non‐diabetic controls and explored whether study‐level differences in LFC varied according to IPFD burden. Seventeen studies (2142 participants) were included. Individuals with T2DM had significantly higher LFC than non‐diabetic controls (standardised mean difference [SMD] 0.89, 95% CI 0.60–1.18). In exploratory subgroup analyses, liver fat excess was larger in studies with mean IPFD ≥ 10% than in those with IPFD < 10% (SMD 1.20 vs. 0.62; p = 0.04), though this finding was not consistently retained in leave‐one‐out analyses. Alternative IPFD cutoffs yielded directionally similar but non‐significant subgroup differences. Study‐level differences in IPFD were associated with differences in LFC ( β = 0.383, p = 0.006) in univariable meta‐regression, but not after BMI adjustment. These findings suggest that higher IPFD is associated with greater liver fat excess in T2DM at the study level. Individual‐level analyses are now warranted to clarify this relationship.
- 19 October 2026
- Published by Wiley in Liver International
- Vol. 46 (11) , e70934
Open AccessExcess Liver Fat in Type 2 Diabetes Stratified by Intrapancreatic Fat Deposition: A Meta‐Analysis of Dual‐Organ MRI Studies
Both liver fat content (LFC) and intrapancreatic fat deposition (IPFD) are frequently increased in Type 2 diabetes mellitus (T2DM). We meta‐analysed dual‐organ MRI studies comparing LFC between individuals with T2DM and non‐diabetic controls and explored whether study‐level differences in LFC varied according to IPFD burden. Seventeen studies (2142 participants) were included. Individuals with T2DM had significantly higher LFC than non‐diabetic controls (standardised mean difference [SMD] 0.89, 95% CI 0.60–1.18). In exploratory subgroup analyses, liver fat excess was larger in studies with mean IPFD ≥ 10% than in those with IPFD < 10% (SMD 1.20 vs. 0.62; p = 0.04), though this finding was not consistently retained in leave‐one‐out analyses. Alternative IPFD cutoffs yielded directionally similar but non‐significant subgroup differences. Study‐level differences in IPFD were associated with differences in LFC ( β = 0.383, p = 0.006) in univariable meta‐regression, but not after BMI adjustment. These findings suggest that higher IPFD is associated with greater liver fat excess in T2DM at the study level. Individual‐level analyses are now warranted to clarify this relationship.
- Open Access
- 20 July 2026
- Published by Springer Nature in Current Obesity Reports
- Vol. 15 (1) , 60
Effects of Lifestyle Modification on Intrapancreatic Fat Deposition: A Systematic Review and Meta-Analysis
Background & Aims: Lifestyle modification is a well-established approach for improving metabolic health and reducing ectopic fat accumulation in the liver. The Melbourne Consensus has recently highlighted intrapancreatic fat deposition (IPFD) as an important fat depot, playing a key role in the development of both endocrine and exocrine pancreatic diseases. Nevertheless, the existing literature on the impact of lifestyle modification on IPFD has not been systematically synthesized. We conducted a comprehensive systematic review and meta-analysis to assess the effects of lifestyle modification on IPFD. Methods: A systematic literature search was conducted in PubMed and Embase databases to identify interventional studies evaluating the effects of lifestyle modification on IPFD measured by magnetic resonance-based techniques. Data were meta-analyzed using a random-effects model. Statistical heterogeneity was assessed using the I² statistic, and publication bias was evaluated with Egger’s test. Results: A total of 23 studies were included. Lifestyle modification resulted in a significant reduction in IPFD (standardized mean difference [SMD] -0.26, 95% CI -0.36 to -0.16; p2 =12.9%). The pooled absolute reduction in MRI-measured IPFD was −1.02 % (95% CI −1.30 to −0.73; p2 =0%). Subgroup analyses showed the largest numerical reduction in IPFD with combined diet-and-exercise interventions (SMD -0.41, 95% CI -0.81 to -0.02, I 2 =29.4%), followed by exercise alone (SMD -0.26, 95% CI -0.36 to -0.15, I 2 =0%) and diet alone (SMD -0.22, 95% CI -0.37 to -0.08, I 2 =27.9%). However, differences between intervention types were not statistically significant (p=0.40). There was no evidence of publication bias (p = 0.78). Conclusion: Lifestyle modification is an effective non-pharmacological approach for reducing IPFD, with combined diet-and-exercise interventions showing the largest numerical effect. These findings support the potential of structured lifestyle modification programs to reduce IPFD and may have implications for the prevention and management of pancreatic diseases.
- 20 July 2026
- Published by Springer Nature in Current Obesity Reports
- Vol. 15 (1) , 60
Open AccessEffects of Lifestyle Modification on Intrapancreatic Fat Deposition: A Systematic Review and Meta-Analysis
Background & Aims: Lifestyle modification is a well-established approach for improving metabolic health and reducing ectopic fat accumulation in the liver. The Melbourne Consensus has recently highlighted intrapancreatic fat deposition (IPFD) as an important fat depot, playing a key role in the development of both endocrine and exocrine pancreatic diseases. Nevertheless, the existing literature on the impact of lifestyle modification on IPFD has not been systematically synthesized. We conducted a comprehensive systematic review and meta-analysis to assess the effects of lifestyle modification on IPFD. Methods: A systematic literature search was conducted in PubMed and Embase databases to identify interventional studies evaluating the effects of lifestyle modification on IPFD measured by magnetic resonance-based techniques. Data were meta-analyzed using a random-effects model. Statistical heterogeneity was assessed using the I² statistic, and publication bias was evaluated with Egger’s test. Results: A total of 23 studies were included. Lifestyle modification resulted in a significant reduction in IPFD (standardized mean difference [SMD] -0.26, 95% CI -0.36 to -0.16; p2 =12.9%). The pooled absolute reduction in MRI-measured IPFD was −1.02 % (95% CI −1.30 to −0.73; p2 =0%). Subgroup analyses showed the largest numerical reduction in IPFD with combined diet-and-exercise interventions (SMD -0.41, 95% CI -0.81 to -0.02, I 2 =29.4%), followed by exercise alone (SMD -0.26, 95% CI -0.36 to -0.15, I 2 =0%) and diet alone (SMD -0.22, 95% CI -0.37 to -0.08, I 2 =27.9%). However, differences between intervention types were not statistically significant (p=0.40). There was no evidence of publication bias (p = 0.78). Conclusion: Lifestyle modification is an effective non-pharmacological approach for reducing IPFD, with combined diet-and-exercise interventions showing the largest numerical effect. These findings support the potential of structured lifestyle modification programs to reduce IPFD and may have implications for the prevention and management of pancreatic diseases.
- Open Access
- 21 May 2026
- Published by Springer Nature in Current Obesity Reports
- Vol. 15 (1)
Burden of Intrapancreatic Fat Deposition in Type 2 Diabetes and the Role of Obesity: A Systematic Review and Meta-Analysis
Background: Growing evidence supports a role for high intrapancreatic fat deposition (IPFD) in the pathogenesis of type 2 diabetes mellitus (T2DM); however, the magnitude of this association and the extent to which it is influenced by body mass index (BMI), liver fat content (LFC), and age remain uncertain. Objective: To quantitatively evaluate IPFD measured by magnetic resonance imaging (MRI) in individuals with T2DM and to investigate study-level factors contributing to between-study variability. Methods: We systematically searched PubMed and Embase for observational studies comparing MRI-measured IPFD in individuals with T2DM versus non-diabetic controls, excluding studies in which IPFD quantification was performed using AI-based models. Pooled standardized mean differences (SMDs) were estimated using a restricted maximum likelihood approach with Hartung-Knapp adjustment. Heterogeneity was explored through subgroup, meta-regression, and sensitivity analyses. Results: Thirty studies ( n =3,980) were included. Individuals with T2DM had significantly higher IPFD than non-diabetic controls (SMD 1.13, 95% CI 0.74 to 1.51), with no significant differences when stratified by pancreatic region, MRI technique, geographic region, sample size, and risk of bias. In multivariable models, BMI remained the only consistent moderating covariate, and the excess IPFD in T2DM persisted after adjusting for BMI, LFC, and age (intercept=0.797, p=0.010, false discovery rate-adjusted p=0.018). Advanced heterogeneity exploration identified no structural outliers, and the pooled effect size remained consistent across multiple sensitivity analyses. Conclusion: T2DM is associated with substantially higher MRI-quantified IPFD, independent of study-level differences in BMI, LFC, and age. Although causality cannot be inferred, these findings support the hypothesis that IPFD may be involved in the underlying mechanism of T2DM. They also suggest that high IPFD could represent a metabolic hallmark, with potential implications for risk stratification and therapeutic targeting.
- 21 May 2026
- Published by Springer Nature in Current Obesity Reports
- Vol. 15 (1)
Open AccessBurden of Intrapancreatic Fat Deposition in Type 2 Diabetes and the Role of Obesity: A Systematic Review and Meta-Analysis
Background: Growing evidence supports a role for high intrapancreatic fat deposition (IPFD) in the pathogenesis of type 2 diabetes mellitus (T2DM); however, the magnitude of this association and the extent to which it is influenced by body mass index (BMI), liver fat content (LFC), and age remain uncertain. Objective: To quantitatively evaluate IPFD measured by magnetic resonance imaging (MRI) in individuals with T2DM and to investigate study-level factors contributing to between-study variability. Methods: We systematically searched PubMed and Embase for observational studies comparing MRI-measured IPFD in individuals with T2DM versus non-diabetic controls, excluding studies in which IPFD quantification was performed using AI-based models. Pooled standardized mean differences (SMDs) were estimated using a restricted maximum likelihood approach with Hartung-Knapp adjustment. Heterogeneity was explored through subgroup, meta-regression, and sensitivity analyses. Results: Thirty studies ( n =3,980) were included. Individuals with T2DM had significantly higher IPFD than non-diabetic controls (SMD 1.13, 95% CI 0.74 to 1.51), with no significant differences when stratified by pancreatic region, MRI technique, geographic region, sample size, and risk of bias. In multivariable models, BMI remained the only consistent moderating covariate, and the excess IPFD in T2DM persisted after adjusting for BMI, LFC, and age (intercept=0.797, p=0.010, false discovery rate-adjusted p=0.018). Advanced heterogeneity exploration identified no structural outliers, and the pooled effect size remained consistent across multiple sensitivity analyses. Conclusion: T2DM is associated with substantially higher MRI-quantified IPFD, independent of study-level differences in BMI, LFC, and age. Although causality cannot be inferred, these findings support the hypothesis that IPFD may be involved in the underlying mechanism of T2DM. They also suggest that high IPFD could represent a metabolic hallmark, with potential implications for risk stratification and therapeutic targeting.
- 10 March 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 236, 113149
High prevalence of fatty pancreas disease in type 2 diabetes mellitus: a meta-analysis
- 10 March 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 236, 113149
High prevalence of fatty pancreas disease in type 2 diabetes mellitus: a meta-analysis
- 1 November 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (11)
Efficacy of 5-aminosalicylic acid continuation versus discontinuation in patients with ulcerative colitis escalated to advanced therapy: a systematic review and meta-analysis of adjusted effect estimates
Background and Aims: The benefit of continuing 5-aminosalicylates (5-ASA) in patients with ulcerative colitis (UC) escalated to advanced therapies remains uncertain. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of 5-ASA continuation vs discontinuation in this population. Methods: We systematically searched the PubMed, Embase, and Cochrane databases for studies comparing 5-ASA continuation vs discontinuation in adult patients with UC escalated to advanced therapies. Adjusted effect estimates were pooled using random-effects models. Results: The meta-analysis comprised nine observational cohorts and two studies presenting post-hoc analyses from eight clinical trials. We included 11 487 patients, with 9105 assigned to 5-ASA continuation and 2382 to 5-ASA discontinuation. Compared to discontinuation, 5-ASA continuation was associated with decreased odds of achieving clinical remission (adjusted odds ratio [aOR] 0.72; 95% CI 0.52-0.99; I2 = 0%). There were no significant differences between groups for corticosteroid-free clinical remission (aOR 0.71; 95% CI 0.41-1.23; I2 = 0%), clinical response (aOR 0.94; 95% CI 0.69-1.28; I2 = 0%), endoscopic healing (OR 1.00; 95% CI 0.71-1.41; I2 = 54.6%), and biochemical remission (aOR 1.13; 95% CI 0.76-1.68; I2 = 31%). In time-to-event analyses, no significant differences were found between groups for UC-related hospitalization (adjusted hazard ratio [aHR] 0.99; 95% CI 0.86-1.13; I2 = 0%), UC-related surgery (aHR 1.02; 95% CI 0.80-1.29; I2 = 13%), new corticosteroid prescription (aHR 0.97; 95% CI 0.88-1.07; I2 = 0%), composite adverse events (aHR 0.96; 95% CI 0.87-1.06; I2 = 0%), and loss of response (aHR 0.92; 95% CI 0.75-1.12; P = .39; I2 = 61%). Conclusion: In patients with UC escalated to advanced therapies, 5-ASA continuation was associated with decreased odds of achieving clinical remission compared to discontinuation, with no significant differences observed for secondary efficacy or safety endpoints.
- 1 November 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (11)
Efficacy of 5-aminosalicylic acid continuation versus discontinuation in patients with ulcerative colitis escalated to advanced therapy: a systematic review and meta-analysis of adjusted effect estimates
Background and Aims: The benefit of continuing 5-aminosalicylates (5-ASA) in patients with ulcerative colitis (UC) escalated to advanced therapies remains uncertain. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of 5-ASA continuation vs discontinuation in this population. Methods: We systematically searched the PubMed, Embase, and Cochrane databases for studies comparing 5-ASA continuation vs discontinuation in adult patients with UC escalated to advanced therapies. Adjusted effect estimates were pooled using random-effects models. Results: The meta-analysis comprised nine observational cohorts and two studies presenting post-hoc analyses from eight clinical trials. We included 11 487 patients, with 9105 assigned to 5-ASA continuation and 2382 to 5-ASA discontinuation. Compared to discontinuation, 5-ASA continuation was associated with decreased odds of achieving clinical remission (adjusted odds ratio [aOR] 0.72; 95% CI 0.52-0.99; I2 = 0%). There were no significant differences between groups for corticosteroid-free clinical remission (aOR 0.71; 95% CI 0.41-1.23; I2 = 0%), clinical response (aOR 0.94; 95% CI 0.69-1.28; I2 = 0%), endoscopic healing (OR 1.00; 95% CI 0.71-1.41; I2 = 54.6%), and biochemical remission (aOR 1.13; 95% CI 0.76-1.68; I2 = 31%). In time-to-event analyses, no significant differences were found between groups for UC-related hospitalization (adjusted hazard ratio [aHR] 0.99; 95% CI 0.86-1.13; I2 = 0%), UC-related surgery (aHR 1.02; 95% CI 0.80-1.29; I2 = 13%), new corticosteroid prescription (aHR 0.97; 95% CI 0.88-1.07; I2 = 0%), composite adverse events (aHR 0.96; 95% CI 0.87-1.06; I2 = 0%), and loss of response (aHR 0.92; 95% CI 0.75-1.12; P = .39; I2 = 61%). Conclusion: In patients with UC escalated to advanced therapies, 5-ASA continuation was associated with decreased odds of achieving clinical remission compared to discontinuation, with no significant differences observed for secondary efficacy or safety endpoints.